Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2017

View Archived Issues

AAV-mediated liver delivery of secretable GAA improves long-term survival in Pompe disease mice

Tasigna receives approval in Japan for treatment of pediatric chronic myeloid leukemia

SK Chemicals launches SKYZoster shingles vaccine in South Korea

Pfizer enrolling participants in phase I study of PF-06863135

Clover Biopharmaceuticals receives approval to initiate clinical trials of SCB-808 in China

FDA accepts NDA for OTX-101

Maruho and RaQualia enter worldwide license agreement

Celgene researchers report compounds with antiprotozoal activity

Agents for the treatment of malaria described in Celgene patent

P2X7 receptor antagonists for pain reported in Shionogi patent

Beijing Jacobio Pharmaceuticals patents SHP-2 inhibitors

Pramana Pharmaceuticals patent describes glucose-dependent insulinotropic receptor agonists

Lilly initiates phase II study of LY-3002813 and LY-3202626 in early symptomatic Alzheimer's disease

Athenex receives U.K. promising innovative medicine designation for Oraxol

Combination therapy with gedatolisib shows promising preliminary antitumor activity in breast cancer

Kaiso as a potential new biomarker and therapeutic target in TNBC

NeuroRx enters agreement for clinical trial of NRX-100/NRX-101 regimen

Phase II data show safety of combining Ra-223 with hormonal therapy and denosumab

Phase III SIERRA study of Iomab-B cleared to continue enrollment

Phase II safety data for abemaciclib as treatment of brain metastases secondary to HR+ breast cancer

First patient enrolled in phase III OVAL study of VBL Therapeutics' VB-111

Keytruda approved for new indication in Japan

Innovation Pharmaceuticals reports preliminary data from phase IIa study of Kevetrin

Protalix Biotherapeutics' pegunigalsidase alfa granted orphan drug status in E.U.

New phase III trial explores use of TSC in newly diagnosed GBM

CFDA designates lenvatinib for priority review and approval for HCC

Bayer initiates phase III studies in Japan of molidustat in nondialysis patients with renal anemia

Eli Lilly's Zyprexa approved for chemotherapy-induced nausea and vomiting in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...